April 13, 2026
FDA issues complete response letter to Replimune’s RP1 for melanoma
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Replimune Group’s biologics licence application (BLA) concerning the RP1 therapy in combination with nivolumab for advanced melanoma.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







